Clinical Hub Aberystwyth
Your Health Matters
Novel technologies for diagnosing and monitoring pulmonary diseases
​
IRAS ID 187325
This is a collaborative study between academia and the NHS which seeks to harness the latest scientific advances to improve the care of patients with different respiratory diseases.
​
We are indebted to the many patients who have contributed to, and continue to contribute to this study.
​
Thank you.
​
This website is for you to see how you are aiding important clinical advances and allows you to contact us should you wish.
'Novel Technologies' launch meeting, April 2016
From left to right:
Top row: Dr. Subhamay Ghosh, Prof. Luis Mur - Scientific Lead, Prof. Keir Lewis - Clinical Lead, Denisa Asandei, Adrian Mironas, Dr. Priya Sai-Giridhar
​
Bottom row: Dr. Tim Tasibey, Dr. Kirsty Hett, Rachel Paes De Araujo
Research
The 'Novel Technologies' study was launched in April of 2016 and it focuses on identifying important chantges in saliva, sputum, serum and pleural fluids which are linked to:
​
-
The presence of lung cancer
-
A particular stage of lung cancer
-
A particular type of lung cancer; (e.g. Non-small cell lung cancer [NSCLC]; small cell lung cancer [SCLC])
-
COPD disease status and the triggering of exacerbation (a flare-up or episode when your breathing gets markedly worse)
-
informing the treatment of sleep apnoea
Meet the "Novel Tech" Team
_edited.jpg)
"Novel Tech" publications
T Kramarić, RP de Araujo, K Love, T Asibey-Berko, S Ghosh, KE Lewis, LAJ Mur. (2022) Systemic changes in monoacylglycerols could be an indicator of inflammation in chronic obstructive pulmonary disease (COPD) patients Thorax 77 (Suppl 1), A90-A91
​
O’Rourke, S.; Thomas, S.; Lewis, C.; Bowen, S.; Mur, L.; Lewis, K. 13 (2021) The effect of continuous positive airway pressure (CPAP) on key plasma metabolites identifying obstructive sleep apnoea hypopnoea syndrome (OSAHS). BMJ Open Respiratory Research 2021, 8, A6-A7, doi:10.1136/bmjresp-2021-bssconf.11.
Wolffs, K.L.; Mansfield, B.; Bruce, R.T.; Huang, P.; Schepelmann, M.; Brennan, S.C.; Verckist, L.; Adriaensen, D.; De Araújo, R.P.; Mur, L.A.J., et al. Calcium-sensing receptor antagonism as a novel therapeutic for pulmonary fibrosis. medRxiv 2020, 10.1101/2020.03.12.20034751, 2020.2003.2012.20034751, doi:10.1101/2020.03.12.20034751.
Mansfield, B.; Ho, T.-R.; Mudway, I.; Lugg, S.T.; Corrigan, C.J.; Ward, J.P.T.; Thickett, D.; Prytherch, Z.; Scofield, S.; Kemp, P.J., et al. Calcium-sensing receptor antagonists, calcilytics, prevent activation of human dendritic and epithelial cells by urban particulate matter. European Respiratory Journal 2020, 56, 1970, doi:10.1183/13993003.congress-2020.1970.
Kramarić, T.; Thomas, S.; Love, K.; Bond, I.; Rooke, D.; Mur, L.; Lewis, K. Late Breaking Abstract - Early exploratory use of omic approaches to assess metabolite changes in COPD. European Respiratory Journal 2020, 56, 322, doi:10.1183/13993003.congress-2020.322.
Paes de Araujo, R.; Bertoni, N.; Seneda, A.L.; Felix, T.F.; Carvalho, M.; Lewis, K.E.; Hasimoto, E.N.; Beckmann, M.; Drigo, S.A.; Reis, P.P., et al. Defining Metabolic Rewiring in Lung Squamous Cell Carcinoma. Metabolites 2019, 9, doi:10.3390/metabo9030047.
Mansfield, B.; Huang, P.; Bruce, R.; Ho, T.-R.; Du, X.; Huang, Q.; Wang, W.; Lugg, S.; Ford, W.; Kidd, E., et al. T4 Calcium-sensing receptor antagonists (calcilytics) as a novel therapeutic for alarmin-driven inflammatory lung disease. Thorax 2019, 74, A2-A3, doi:10.1136/thorax-2019-BTSabstracts2019.4.
Mur, L.; Mironas, A.; Paes, R.; O'Shea, K.; Lewis, K. Non-targeted integrative multi-omics approaches on sputum reveal potential diagnostic and monitoring biomarkers for respiratory diseases. European Respiratory Journal 2017, 50, PA375, doi:10.1183/1393003.congress-2017.PA375.